Childhood solid tumours
Gene: BRCA2
As discussed at the Genomics Cancer Panel Workshop, 16th July 2019: the group agreed that there is enough evidence to rate this gene green.Created: 2 Aug 2019, 11:03 a.m. | Last Modified: 2 Aug 2019, 11:03 a.m.
Panel Version: 1.27
Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal
Phenotypes
Hereditary Breast and Ovarian Cancer
Phenotypes for gene: BRCA2 were changed from Wilms tumor, 194070; Fanconi Anaemia; {Breast cancer, male, susceptibility to}, 114480; Prostate cancer, 176807; {Medulloblastoma}, 155255; {Glioblastoma 3}, 613029; Fanconi Anemia; Hereditary Breast and Ovarian Cancer; Fanconi anemia, complementation group D1, 605724; {Breast-ovarian cancer, familial, 2}, 612555; Pancreatic cancer, 613347 to Fanconi anemia, complementation group D1, OMIM:605724; Wilms tumor, OMIM:194070; {Glioblastoma 3}, OMIM:613029; {Medulloblastoma}, OMIM:155255
Source NHS GMS was added to BRCA2. Added phenotypes Hereditary Breast and Ovarian Cancer for gene: BRCA2 Publications for gene BRCA2 were changed from to 23788249
Source Expert List was added to BRCA2. Rating Changed from Green List (high evidence) to Green List (high evidence)
This gene has been classified as Green List (High Evidence).
Model of inheritance for gene BRCA2 was changed to BIALLELIC, autosomal or pseudoautosomal
BRCA2 was added to Paediatric congenital malformation-dysmorphism-tumour syndromes panel. Sources: UKGTN
Model of inheritance for gene BRCA2 was changed to BIALLELIC, autosomal or pseudoautosomal
Model of inheritance for gene BRCA2 was changed to BIALLELIC, autosomal or pseudoautosomal
BRCA2 was added to Paediatric congenital malformation-dysmorphism-tumour syndromes panel. Sources: Illumina TruGenome Clinical Sequencing Services
BRCA2 was added to Paediatric congenital malformation-dysmorphism-tumour syndromes panel. Sources: Radboud University Medical Center, Nijmegen